Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M609636200 on March 13, 2007

J. Biol. Chem., Vol. 282, Issue 26, 18960-18968, June 29, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/26/18960    most recent
M609636200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herbert, A. P.
Right arrow Articles by Barlow, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herbert, A. P.
Right arrow Articles by Barlow, P. N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Structure Shows That a Glycosaminoglycan and Protein Recognition Site in Factor H Is Perturbed by Age-related Macular Degeneration-linked Single Nucleotide Polymorphism*Formula

Andrew P. Herbert{ddagger}, Jon A. Deakin§, Christoph Q. Schmidt{ddagger}, Bärbel S. Blaum{ddagger}, Claire Egan{ddagger}, Viviana P. Ferreira, Michael K. Pangburn, Malcolm Lyon§, Dusan Uhrín{ddagger}, and Paul N. Barlow{ddagger}1

From the {ddagger}Edinburgh Biomolecular NMR Unit, School of Chemistry and School of Biological Sciences, University of Edinburgh, West Mains Road, Edinburgh EH9 3JJ, Scotland, United Kingdom, §Cancer Research UK Glyco-Oncology Group, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, United Kingdom, and the Department of Biochemistry, University of Texas Health Science Center, Tyler, Texas 75703

Received for publication, October 12, 2006 , and in revised form, January 31, 2007.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
A common single nucleotide polymorphism in the factor H gene predisposes to age-related macular degeneration. Factor H blocks the alternative pathway of complement on self-surfaces bearing specific polyanions, including the glycosaminoglycan chains of proteoglycans. Factor H also binds C-reactive protein, potentially contributing to noninflammatory apoptotic processes. The at risk sequence contains His (rather than Tyr) at position 402 (384 in the mature protein), in the seventh of the 20 complement control protein (CCP) modules (CCP7) of factor H. We expressed both His402 and Tyr402 variants of CCP7, CCP7,8, and CCP6-8. We determined structures of His402 and Tyr402 CCP7 and showed them to be nearly identical. The side chains of His/Tyr402 have similar, solvent-exposed orientations far from interfaces with CCP6 and -8. Tyr402 CCP7 bound significantly more tightly than His402 CCP7 to a heparin affinity column as well as to defined-length sulfated heparin oligosaccharides employed in gel mobility shift assays. This observation is consistent with the position of the 402 side chain on the edge of one of two glycosaminoglycan-binding surface patches on CCP7 that we inferred on the basis of chemical shift perturbation studies with a sulfated heparin tetrasaccharide. According to surface plasmon resonance measurements, Tyr402 CCP6-8 binds significantly more tightly than His402 CCP6-8 to immobilized C-reactive protein. The data support a causal link between H402Y and age-related macular degeneration in which variation at position 402 modulates the response of factor H to age-related changes in the glycosaminoglycan composition and apoptotic activity of the macula.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Age-related macular degeneration (AMD)2 is a leading cause of irreversible visual impairment in the elderly (1). The densely packed photoreceptors in the macula are maintained by the underlying retinal pigment epithelium (RPE) (2). A unique pentalaminar extracellular matrix (ECM), the Brüch's membrane, separates the RPE from the fenestrated endothelium of the choroidal vasculature. In early AMD, fatty deposits, called drusen, appear between Brüch's membrane and the RPE (3). Early AMD may progress to severe forms (4), characterized by RPE-cell death and atrophy of the photoreceptor layer, or choroidal neovascularization.

Drusen are rich in cell breakdown products and proteins of the complement system (5). Complement (6, 7) is a potent mediator of inflammation. An association between AMD and the gene (CFH) for the complement regulator factor H (fH) was demonstrated by Hageman et al. (8) and confirmed independently by others (9-12). Hageman et al. (8) additionally reported the RPE to be a source of fH, while drusen components C3a and C5a have been implicated in neovascularization in mouse models of AMD (13), strengthening further the evidence for an AMD-complement link.

The at-risk allele that has received most attention, in CFH exon 9 (rs1061170; 1277T > C), encodes a His rather than a Tyr at position 402 (residue 384 of the mature fH) and is present in ~35% of individuals of European descent. Homozygous individuals have a 6-fold increased risk of developing AMD, whereas heterozygotes are 2.5 times more susceptible (14). Doubts over a causal link between the H402Y variation and the etiology of AMD have been raised by the identification of 20 synonymous or intronic single nucleotide polymorphisms (SNPs) in a 123-kb region overlapping CFH that are even more strongly associated with AMD (15, 16). Moreover, variations in genes encoding complement factor 2 (C2) and complement factor B (BF) also strongly influence risk, as does an SNP in a gene, LOC387715, of unknown function (16, 17). Other risk factors for AMD include smoking, diet, obesity, and underlying vascular disease (18). Detailed investigations of the structural and functional consequences of the Tyr402 variation in fH are thus required to shed light on the putative role of H402Y in the etiology of AMD.

Factor H is a plasma glycoprotein (155 kDa, 500-800 µg/ml) (19) that controls the alternative pathway (AP) of complement activation (20). The AP operates at "tick over" level on any surface, self or foreign, but is normally amplified exclusively on foreign surfaces, thanks in part to the selective action of fH. Factor H recognizes and binds to self-surfaces via sialic acid and glycosaminoglycan (GAG) chains of proteogylycans (21), whereupon its complement-regulating properties are enhanced (20). Factor H destroys the surface-deposited convertases, which are made up from fragments of C3 and factor B, that drive the amplification loop within the AP. Self-cells carry additional, membrane-bound, regulators of the AP. Consequently, fH is particularly important for protecting self-surfaces not enclosed by a cell membrane.

Factor H consists of 20 tandem complement control protein modules (CCPs) (22). The AMD-linked His/Tyr402 variation is in CCP7, which contributes to one of two putative sites that bind C-reactive protein (CRP) (23, 24) and to one of at least three GAG-binding modules in fH (25). Module 7 therefore potentially participates in the ability of fH to selectively act upon convertases formed on self-surfaces. Indeed, a recent report (26) indicated that His402 fH binds less strongly to retinal epithelial cell surfaces than Tyr402 fH. However, the specificities and the relative affinities of the various GAG-binding sites of fH have not yet been established. Each of the three (or four) sites may contribute in a combinatorial fashion to the capacity of factor H to recognize host surfaces (20), depending on the tissue context and the circumstances. In vitro assays cannot emulate accurately physiological conditions, making it difficult to test hypotheses concerning differential GAG binding specificities of the His402 and Tyr402 allotypes of factor H. For example, when such studies are performed using intact fH, the GAG recognition sites may compete or cooperate in an artifactual manner, and these problems are compounded by the fact that most GAG preparations are heterogeneous. A recent study (27) intriguingly reported differential GAG binding by His402 and Tyr402 versions of a recombinantly expressed fragment of fH consisting of CCPs 6, 7 and 8 (i.e. CCP6-8).

In the current atomic resolution study of the H402Y polymorphism, we too chose to focus primarily on CCP7 and its neighboring modules. Adopting a structural approach, we characterized the interaction of this site with chemically defined GAGs. We show that a causal link between His402 fH and disease is feasible. Residue 402 occupies a critical position on a face of CCP7 that recognizes GAGs. Variation at this position will modulate the ability to distinguish between GAGs according to type and density of sulfation. The overlapping binding site for CRP is also affected.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Isolation of His402 and Tyr402 Allotypic Variants of Human Factor H—Factor H was purified as described (28) from normal human plasma (Stewart Regional Blood Bank, Tyler, TX) of different individuals homozygous at the 402 position. The His402 and Tyr402 allotypic variants of the pure factor H were confirmed by mass spectrometry following purification.

Expression of Protein and NMR—DNA sequences for the following segments of fH (numbered according to full-length protein, i.e. before removal of secretion signal) were cloned into the Pichia pastoris expression vector pPICZ{alpha}: residues 386-444 (CCP7), 386-507 (CCP7,8), and 321-507 (CCP6-8). In each case, DNA encoding both Tyr and His at position 402 was prepared. Expressed proteins were directed to the secretory pathway by placing the coding sequence behind the Saccharomyces cerevisiae {alpha}-factor secretion sequence.

Following transformation into P. pastoris strain KM71H, proteins were expressed in a fermentor. Where appropriate, proteins were isotopically labeled in batches of 0.8 liters (initial volume) of cell culture as described (29). Cation exchange chromatography was used to purify all the proteins. Identity of the purified Tyr402 and His402 CCP7 proteins was confirmed using mass spectrometry. Yields were in the region of 1 mg of pure protein/g of wet cells.

NMR spectra were acquired on Bruker AVANCE 600- and 800-MHz spectrometers using 5-mm probes. Data for resonance assignments were acquired at 298 K on a 0.9 mM sample of 13C,15N CCP7 in 20 mM sodium acetate, at pH 5.2. 15N-Edited and 13C-edited NOESY-HSQC experiments were acquired with mixing times of 150 ms.

Resonance Assignment and Structure Calculation—Nearly complete backbone and side chain assignments were achieved using the CCPN (30) program ANALYSIS (Table 1). A series of 15N,1H HSQC experiments over the pH range 5.0-7.4 allowed assignments of backbone amide 15N and protons at the higher pH. Returning to the pH-5.2 data, resolved peaks in 15N NOESY and 13C NOESY spectra were picked manually and partially assigned where it was possible to do so without ambiguity. Hydrogen bonds were detected using a two-dimensional HNCO experiment (31) and translated into distance restraints (32). All proline residues were deemed trans (33). Chemical shifts, partially assigned NOESY spectra, and hydrogen bond-derived restraints were supplied to the ARIA 2.0 (34) and crystallography and NMR system (CNS) (35) protocols. Eight iterations of filtering, reassignment, and recalibration were performed, each based on the lowest overall energy structures from the previous iteration, followed by a final refinement in explicit water. QUEEN (36) was used to validate structures, restraints, and assignments.


View this table:
[in this window]
[in a new window]

  		TABLE 1
 
Heparin Affinity Chromatography and Gel Mobility Shift Assay (GMSA)—Protein samples (0.05 mM in 1 ml) in phosphate-buffered saline (PBS) were individually loaded onto either a self-packed heparan sulfate-agarose (Sigma) column (0.5 x 10 cm) or a Poros 20HE (0.46 x 10 cm, Applied Biosystems) heparin affinity chromatography column equilibrated with PBS and eluted with a linear gradient from PBS to PBS supplemented to 1 M sodium chloride. The His402 CCP7 eluted at a lower salt concentration than Tyr402 CCP7. Subsequently the two variants of the single modules were combined prior to resolving them on the heparin column.

Oligosaccharides were prepared from low molecular weight heparin (37) or dermatan sulfate (38), fluorophore-labeled species were produced by attachment of 2-aminoacridone to the oligosaccharide reducing end, and the GMSA was performed, all as described previously (39). Briefly, 2-aminoacridone-tagged oligosaccharides were combined with either Tyr402 or His402 CCP7 (at concentrations indicated in Figs. 1b and 2, a and c) in a total volume of 10 µl of PBS containing 25% (v/v) glycerol for 15 min (room temperature). Samples were then loaded on a 1% agarose gel in 10 mM Tris-HCl, pH 7.4, and 1 mM EDTA. Electrophoresis was performed (200 V, 8-15 min) in a horizontal agarose electrophoresis system, using an electrophoresis buffer comprising 40 mM Tris/acetic acid, 1 mM EDTA, pH 8.0. Immediately thereafter, the 2-aminoacridone-tagged oligosaccharides were visualized.

Surface Plasmon Resonance—This was performed on a BiacoreTM T100 instrument by immobilizing 717 response units of CRP on a CM5 chip using standard amine coupling. Ligand preconcentration prior to immobilization was performed using 25 µg·ml-1 CRP in 10 mM sodium acetate buffer, pH 5.5. The analysis was performed at 25 °C using 10 mM HEPES, 150 mM NaCl, 0.05% surfactant P20, pH 7.4, as running buffer. Surface consistency and regeneration efficiency tests were performed using 32 µM Tyr402 CCP6-8 and indicated that the surface was stable and regeneration was effective (data not shown).

Locating the Polyanion Binding Site by Chemical Shift Mapping—Initially, 15N-1H HSQC spectra were acquired (600 MHz, cryogenic probe) on 15N-labeled CCP7 samples (20 µM in 20 mM sodium acetate (deuterated), pH 5.0, 25 °C) in the presence of 0-40 µM fully sulfated, heparin-derived tetrasaccharide (purified from a mixed tetrasaccharide fraction by strong anion-exchange high-pressure liquid chromatography and characterized by disaccharide analysis). The titration was repeated at pH 7.4 (20 mM potassium phosphate) plus 140 mM sodium chloride, and again at pH 7.4 (20 mM potassium phosphate, no additional salt) with 0-160 µM tetrasaccharide (saturation not reached). Spectra of the complex were assignable due to incremental movement of cross-peaks during the titration. The polyanion-binding site was inferred on the basis of amide 15N and 1H resonances that exhibited the largest heparin-induced combined chemical shift perturbation (CSP) (40).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Homing in on Module 7—The His and Tyr allotypic variants of factor H show indistinguishable affinity for a heparin column (Fig. 1a). To achieve a comparison of affinities for more structurally defined GAG ligands, we used the GMSA (39) to explore binding to size-fractionated heparin oligosaccharides. In this assay, the extent of binding of a fluorescently tagged oligosaccharide is judged by the proportional retardation of its normal migration toward the anode. As measured by GMSA, the two variants of full-length human factor H bind equally well to chemically pure, fully sulfated heparin-derived dodecasaccharide (Fig. 1b). A similar result was obtained for a tetrasaccharide (not shown). Because factor H contains multiple GAG-binding sites that may compete or cooperate in such artificial assays, we adopted a dissection approach. We found that P. pastoris-expressed factor H fragments corresponding to modules 6-8 (CCP6-8), with either His or Tyr at position 402, also bound equally well both to a heparin column (not shown) and to a panel of chemically pure, defined-size, fully sulfated heparin fragments (Fig. 2a). We noted, however, that in previous work, Clark et al. (27) had shown that E. coli-expressed Tyr402 and His402 CCP6-8 exhibited differential binding to various GAG preparations. To explore this issue further, we tested the His402 and Tyr402 variants of isolated CCP7 (expressed in P. pastoris).

Strikingly, the two variants of single-module CCP7 were base line-resolved on a heparin affinity column (pH 7.4) (Fig. 2b). Irrespective of oligosaccharide length, Tyr402 CCP7 retards a higher proportion of heparin than His402 CCP7 according to a GMSA (Fig. 2a). The effect is more pronounced with smaller oligosaccharides and particularly obvious for the di- and tetrasaccharide. A dose-response version of the GMSA, conducted using a fixed amount of the tetrasaccharide (Fig. 2c), reinforced this result. Since the Tyr402 version of CCP7 binds more strongly than the His402 version, this appeared not to be merely a charge-related effect. It also appeared to be GAG-specific, since no such distinction was observed between the variants using a panel of size-fractionated dermatan sulfates in the GMSA (Fig. 2a). Our objective was to focus on the role of disease-linked residue 402. We therefore chose to follow up the clear differences in heparin affinity between variants at the level of the single modules using an atomic resolution structural approach.


Figure 1
View larger version (46K):
[in this window]
[in a new window]

  		FIGURE 1.
Affinity of Tyr402 and His402 allotypic variants of full-length fH for heparin. a, the two proteins elute under identical conditions from a heparin-agarose affinity column. b, both variants bind equally well to a heparin-derived fully sulfated dodecasaccharide according to GMSA (0.25 µg of dodecasaccharide and increasing molar ratios of fH as indicated).

 
Module 7 of fH May Be Instructively Studied in Isolation from Its Neighbors—The N and C termini of CCPs lie at opposite ends of their three-dimensional structures, and neighboring CCPs typically adopt an elongated, end-to-end arrangement (41, 42). Indeed, in fH, just three residues separate CCP6 from CCP7, and steric considerations rule out a side-by-side association. On the other hand, the linker between CCP7 and -8 (five residues) might be long enough to allow CCP8 to fold back alongside CCP7. To assess this possibility, a 1H,15N HSQC spectrum was collected on recombinant Tyr402 CCP7,8 (i.e. the double module) for comparison with the equivalent spectrum of the single module, Tyr402 CCP7 (Fig. 3). Subsequently (following assignment), it was found that the CSPs in CCP7 due to the presence of CCP8 occur only for residues proximal to the CCP7 C terminus. Equivalent results were obtained in the case of His402 CCP7. Thus, the three fH CCPs, CCP6 to -8, must be arranged in an end-to-end, not a side-by-side, fashion, exposing a large surface area of CCP7 for binding to ligands. The structure of CCP7 (see below) further revealed that the Tyr/His402 side chain is located far from either end of the seventh module and is unable to affect intermodular orientations. Therefore, it is reasonable to compare structures of the His/Tyr402 variants of fH by focusing on isolated module CCP7.


Figure 2
View larger version (48K):
[in this window]
[in a new window]

  		FIGURE 2.
Affinity of fH fragments for GAGs. a, comparison of GMSA data for His402 and Tyr402 allotypes of CCP6-8 (top) or CCP7 (middle) with defined length heparin oligosaccharides (degree of polymerization (dp) values refer to the number of monosaccharide units). A 4-fold molar excess of CCP7 was added to 0.5 µg of oligosaccharide, or equimolar amounts of CCP6-8 were added to 0.5 µg of oligosaccharide. Bottom, a comparison of GMSA data for His402 and Tyr402 allotypes of CCP7 with defined length dermatan sulfate oligosaccharide; equimolar amounts of CCP7 were added to 0.5 µg of oligosaccharide. b, a mixture of His402 and Tyr402 CCP7 (single modules) separated on a Poros heparin affinity column. c, in this GMSA, increasing ratios of protein to oligosaccharide, as indicated, were employed to retard the motion of the 2-aminoacridone-tagged heparin-derived tetrasaccharide toward the anode.

 


Figure 3
View larger version (17K):
[in this window]
[in a new window]

  		FIGURE 3.
1H,15N HSCQ spectrum for Tyr402 CCP7 (red) and Tyr402 CCP7,8 (blue). The y axis corresponds to 15N chemical shifts, and the x axis corresponds to 1H chemical shifts, both in ppm.

 
Structure Determination of Tyr402 and His402 CCP7—The 1H-15N HSQC spectra of the CCP7 variants did not change drastically between pH 5.0 and 7.4 (supplemental Fig. 1), legitimizing structure determination at the experimentally convenient lower pH. There were no significant chemical shift changes in HSQC spectra over the range 20-600 µM CCP7 and no nuclear Overhauser effects symptomatic of nontransient self-association, and line widths were inconsistent with oligomerization in the 600 µM NMR samples. Therefore, CCP7 is predominantly monomeric under the conditions used for structure calculations. Nearly complete assignment of nuclei in Tyr402 and His402 CCP7 (see Table 1 and supplemental Fig. 2) was achieved.

The two nearly identical structures (Fig. 4) resemble previously solved CCP structures (43-45). The 402 side chain is solvent-exposed and lies between two exposed nonconserved Tyr side chains (Tyr390 and Tyr393) (Fig. 4b). This face also features His417, Tyr398, and Tyr420 side chains. The arrangement of these and nearby residues is conserved between the two variants so that the only difference between them is localized to position 402. The side chains of Arg404, Lys405, and Lys410 contribute to the main patch of positive charge on CCP7 (Fig. 4c); another positive patch near the module's C terminus arises from Arg444 and Lys446. We next opted to map the binding site on CCP7 for a pure, fully sulfated heparin tetrasaccharide.

Locating the Heparin-binding Site on CCP7 Tyr402 and His402—Initial titrations with the tetrasaccharide, conducted under conditions used for structure determination (low salt, pH 5.2), yielded widespread CSPs (supplemental Fig. 3). Perturbations were similar for both variants, although for His402 CCP7, more heparin was required to produce an equivalent effect. The residues involved are not confined to a single face of CCP7, and these results suggest that a conformational rearrangement, or dimerization, occurs in CCP7 upon binding to tetrasaccharide at nonphysiological pH 5.2. It was therefore impossible to distinguish CSPs caused by direct contacts from those due to structural adjustments.

At approximately physiological ionic strength and pH (140 mM NaCl, 10 mM phosphate buffer, pH 7.4), binding of the tetrasaccharide by Tyr402 CCP7 was undetectable using NMR. At pH 7.4 but with no NaCl (20 mM potassium phosphate), on the other hand, small CSPs were observed in His402 and Tyr402 CCP7 upon titration with tetrasaccharide (Fig. 5a). Thus, low salt is required to achieve significant binding of the tetrasaccharide, but it nonetheless represents a useful small model GAG for further studies. As the ratio of ligand to protein was increased, cross-peaks moved incrementally (consistent with fast exchange), allowing assignments of perturbed cross-peaks. Only a limited set of HSQC cross-peaks (a subset of those that moved at pH 5.2) (the same ones in both variants) experienced significant CSPs during the titration (Figs. 5b), and these corresponded to discrete surface patches on CCP7 and were inferred to represent binding residues (Fig. 5c).

Comparison of CRP Binding by Tyr402 and His402 CCP6-8—Binding of the variants to CRP was compared by surface plasmon resonance. C-reactive protein was attached to the sensor chip. The triple module segment, CCP6-8, not CCP7, was employed as analyte in the anticipation that its greater molecular weight would elicit a larger response upon binding. In these experiments, His402 CCP6-8 exhibits a much lower affinity than its Tyr402 variant for immobilized CRP (Fig. 6).


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Detailed structural and functional comparisons between His402 and Tyr402 allotypic variants of fH are required to investigate the possibility of a causal link between this common SNP and AMD.

The multiple polyanion-binding sites of fH have the capacity to cooperate or interfere with one another under physiological circumstances. We therefore adopted a "dissection-based" approach based on recombinant expression of specific CCPs. This allowed us to focus on the single GAG-binding site that encompasses the disease-associated SNP. Recombinant CCP7, which harbors His/Tyr402, adopts an elongated arrangement with respect to neighboring modules. The 402 side chain is exposed and distant from the module's N or C termini. Focusing on individual CCP7, we found that replacement of Tyr402 with His has structural consequences only for that individual side chain. This SNP thus corresponds to a small and localized change in a large, extended, and flexible protein. It follows that the His/Tyr402 substitution can influence directly only a limited number of the many binding sites distributed along the fH molecule (46, 47). Such a corollary is consistent with the His402 (at risk) variant of fH, present in 35% of Western populations (8), functioning adequately until at least old age.

Module 7 of fH does not contact directly C3 convertase (48) but has putative CRP and GAG-binding sites (25, 49). We therefore sought to ascertain whether His/Tyr402 participates directly in the binding of these ligands by CCP7. Note that we did not investigate the possible existence of higher order fH structures (50) in which nonneighboring modules contact His/Tyr402 nor rule out the possibility that His/Tyr402 participates in some critical fH self-association process.

The His402 variant of the single module, CCP7, binds more weakly than its Tyr402 variant, both to a heparin affinity column and to size-fractionated, fully sulfated heparin oligosaccharides (but no distinction was observed for binding to the less sulfated dermatan sulfate fragments). Since structural differences between the two CCP variants are local to His/Tyr402, it follows that its side chain very likely contributes directly to recognition by CCP7 of GAGs. The participation of His/Tyr402 in a face of the module that contains all Tyr and His residues of CCP7 is noteworthy, since aromatic stacking interactions commonly occur in protein-carbohydrate (51, 52) interactions.

Unlike the isolated module 7, the His402 and Tyr402 variants of the triple module, CCP6-8 (and of intact fH), have similar affinities for heparin. Thus, neighboring modules appear to mask the differential recognition properties exhibited by the two variants of CCP7, at least for the model forms of GAG used in the current study. Indeed, heparin titration of CCP7,8, monitored by a series of HSQC spectra (data not shown), suggests that the 7-8 hinge region contributes to GAG binding (see below). Clark et al. (27) also obtained poor resolution of His402 CCP6-8 from Tyr402 CCP6-8 (both refolded after E. coli expression) on a heparin affinity column. Crucially, however, this group detected differences in binding of these triple-module variants to a panel of chemically defined GAGs, with either variant binding more tightly depending upon GAG type. Thus, the masking effects of modules 6/8 on the discriminatory heparin binding properties of His402 and Tyr402 CCP7s may be less evident in the case of more physiologically relevant ligands. We conducted further analyses using individual CCP7 and a chemically defined sulfated heparin tetrasaccharide. The complex formed between these two molecules provided an experimentally tractable model of a factor H-GAG interaction that affords atomic resolution insights.

At physiological pH, CSP studies suggest two GAG-binding regions on the surface of CCP7. The larger of these is of appropriate dimensions to accommodate the fully sulfated heparin tetrasaccharide used here as a model GAG. It coincides with expectations based on the electrostatic surface of CCP7 and with previously performed mutagenesis (27, 53) (Fig. 4c). Residue 402 is peripheral to this region but in a position to contribute to discrimination between GAG types or sulfation patterns. The second putative GAG-binding region lies at the C terminus of CCP7; this region was also implicated by heparin-titration experiments on the CCP7,8 module pair (not shown), so this result is not an artifact of working with the individual module. Thus, at pH 7.4 and low salt, tetrasaccharide molecules bind in two distinct places on CCP7 (a similar result was obtained with disaccharide; data not shown). Longer GAGs, present on biological surfaces, have the potential to occupy both regions simultaneously (see below) and could bind more tightly and discriminately.


Figure 4
View larger version (71K):
[in this window]
[in a new window]

  		FIGURE 4.
Three-dimensional solution structures of Tyr402 CCP7 and His402 CCP7. a, backbone traces of lowest energy Tyr402 (blue) and His402 (red) structures (stereo view); each 30-member ensemble is superimposed on its nearest-to-mean structure. b, schematic (PyMol; DeLano Scientific, LLC, San Carlos, CA) of Tyr402 (cyan) and His402 (magenta) CCP7, with ball-and-stick representations of all Tyr and His residues and only His/Tyr402 labeled. c, electrostatic surface of Tyr402 (top) and His402 (bottom) CCP7 (GRASP (62)). Red, negative charge; blue, positive charge. Electrostatic surface potential ranged from -10 to +10 kT (where k represents Boltzmann's constant and T is temperature in Kelvin).

 
Coincidence between the two sets of 15 residues whose resonances shifted the most at pH 5.2 and 7.4 is good (12 of 15). At neither pH do the array of Tyr side chains that lie on the same face of CCP7 as residue 402 appear to be involved (apart from Tyr390), despite their potential to participate in stacking interactions with pyranose rings. It remains possible that this tyrosine-rich region could accommodate a less sulfated structure within a longer, more complex physiological ligand, such as heparan sulfate. The two positively charged regions on CCP7 would then bind, as inferred from CSP, to neighboring sulfated structures. Such a pattern of sulfation is found, for example, where the highly sulfated "S domains" terminate in the less sulfated "transition zones" that separate them from the unmodified "NAc domains" (54) of heparan sulfate. According to this model, replacement of Tyr402 by His provides additional potential for electrostatic interactions with sulfate groups but compromises the putative aromatic stacking interactions of the Tyr402 variant. In that case, His402 and Tyr402 CCP7 would bind optimally to GAGs bearing different patterns of sulfation, in agreement with the differences in the affinity of these two protein variants for various forms of heparin measured in this and previous studies (27).

Factor H has two further polyanion-binding sites. The site located in CCP20 additionally mediates cell binding (55) and is critical for many fH functions (56). In one model, CCPs 7 and 20 bind to the same GAG stabilizing a bent back conformation of fH bringing previously distant sites into critical juxtaposition (29). Thus, the Tyr/His variation at 402, via variable affinity for different GAGs, could modulate strongly the ability of fH to act with full effectiveness at specific self-surfaces.


Figure 5
View larger version (44K):
[in this window]
[in a new window]

  		FIGURE 5.
Mapping tetrasaccharide-binding sites on CCP7. a, superimposed HSQC spectra for 20 µM Tyr402 CCP7 before (black) and during (colors) titration with fully sulfated heparin tetrasaccharide. In the expansion, for Phe406, cross-peaks are labeled with the tetrasaccharide concentration (in µM) to illustrate the color-coding used in the figure. b, combined CSP (160 µM tetrasaccharide versus 0 µM tetrasaccharide), plotted as a bar chart against residue number in Tyr402 CCP7. The bar for Tyr402 is highlighted. c, the side chains of 10 residues that undergo largest (combined) CSP are highlighted in pink or purple. Arg404 and Lys405 (in purple) exhibit large CSP and have been implicated by mutagenesis. Tyr402 (exhibits the 11th biggest CSP) and Lys410 (important according to mutagenesis but exhibiting no significant CSP) are colored red.

 


Figure 6
View larger version (23K):
[in this window]
[in a new window]

  		FIGURE 6.
Affinity for C-reactive protein. Sensorgrams to compare binding of Tyr402 CCP6-8 (curves a-c) and His402 CCP6-8 (curves d-f) with immobilized CRP. The analyte concentrations are summarized.

 
Disturbance of GAG binding in fH CCP20 was linked to cases of the microthrombotic kidney disease, atypical hemolytic uremic syndrome (29). Many individuals with membranoproliferative glomerulonephritis type II (dense deposit disease), also associated with Tyr/His402 fH (57), have ocular drusen (5). Brüch's membrane and the glomerular basement membrane are both regions of the ECM that form a selective barrier between fenestrated vasculature with high blood flow and a layer of specialized and metabolically active cells (the RPE or podocytes). In both cases, fH probably plays a crucial role in avoiding complement activation, and consequent inflammation, by the accumulating debris trapped in the ECM, or by the ECM itself; the ECM has no other form of protection from the AP of complement. Significant age-related changes in activity of lysosomal GAG-metabolizing enzymes occur in the macula, manifested in shifts in relative levels of various GAGs within the RPE and Brüch's membrane (58). Thus, the abilities of the His/Tyr402 variants of fH to recognize and thereby protect the Brüch's membrane may fluctuate as the eye ages.

Binding sites for CRP and for GAGs overlap on CCP7, so it was not unexpected to observe that CRP binding is also affected by the His/Tyr402 variation. Furthermore, weaker binding to CRP of the His402 variant of intact fH, compared with the Tyr402 version, has been reported recently (59, 60). This acute phase pentraxin recognizes outer membranes of apoptotic cells, whereupon it promotes opsonization and phagocytosis by activating the classical pathway of complement. The role of fH in this process of apoptotic cell clearance could be to block the AP and thereby diminish inflammatory side effects (23). Accumulating environmental insults, such as oxidative stress, could increase the number of apoptotic cells arising from either the RPE or the overlying photoreceptors, placing extra demands on the machinery needed to clear apoptotic cells in a noninflammatory fashion. This is thought to be the principal role of the CRP-fH interaction (23). Why CRP- and GAG-binding sites on CCP7 overlap is unknown, but simultaneous occupation may be undesirable, with one ligand needing to out-compete the other according to circumstances (61). Hence, relative affinities of fH for these two ligands could be crucial. A plausible disease mechanism would entail an imbalance in the relative affinities displayed by His402 fH for its two ligands, CRP and GAG, in the macula instigated by an age-linked change in the distribution of its target GAGs. When coincident with enhanced local levels of apoptotic activity, the anti-inflammatory properties of the His402 variant could be more readily overwhelmed than in the case of the Tyr402 variant. Thus, a causal link between this SNP and AMD is likely against a background of other genetic variations and environmental and life-style risk factors.


   FOOTNOTES
 
* This work was supported in part by National Institutes of Health Grant DK35081 (to M. K. P.), Cancer Research UK Programme Grant funding (to M. L.), and grants from the Wellcome Trust and Medical Research Council (United Kingdom) (to P. N. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1-S3. Back

1 To whom correspondence should be addressed: Chemistry Bldg., University of Edinburgh, West Mains Rd., Edinburgh EH9 3JJ, Scotland, United Kingdom. Tel.: 44-131-650-4727; Fax: 44-131-650-7155; E-mail: Paul.Barlow{at}ed.ac.uk.

2 The abbreviations used are: AMD, age-related macular degeneration; AP, alternative pathway; CCP, complement control protein module; CRP, C-reactive protein; CSP, chemical shift perturbation; ECM, extracellular matrix; fH, factor H; GAG, glycosaminoglycan; GMSA, gel mobility shift assay; RPE, retinal pigment epithelium; PBS, phosphate-buffered saline; SNP, single nucleotide polymorphism. Back


   ACKNOWLEDGMENTS
 
We thank Juraj Bella for help with data acquisition.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bok, D. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 7053-7054[Free Full Text]
  2. Provis, J. M., Penfold, P. L., Cornish, E. E., Sandercoe, T. M., and Madigan, M. C. (2005) Clin. Exp. Optom. 88, 269-281[Medline] [Order article via Infotrieve]
  3. Johnson, L. V., Leitner, W. P., Staples, M. K., and Anderson, D. H. (2001) Exp. Eye Res. 73, 887-896[CrossRef][Medline] [Order article via Infotrieve]
  4. Nowak, J. Z. (2006) Pharmacol. Rep. 58, 353-363[Medline] [Order article via Infotrieve]
  5. Mullins, R. F., Russell, S. R., Anderson, D. H., and Hageman, G. S. (2000) FASEB J. 14, 835-846[Abstract/Free Full Text]
  6. Walport, M. J. (2001) N. Engl. J. Med. 344, 1140-1144[Free Full Text]
  7. Walport, M. J. (2001) N. Engl. J. Med. 344, 1058-1066[Free Full Text]
  8. Hageman, G. S., Anderson, D. H., Johnson, L. V., Hancox, L. S., Taiber, A. J., Hardisty, L. I., Hageman, J. L., Stockman, H. A., Borchardt, J. D., Gehrs, K. M., Smith, R. J., Silvestri, G., Russell, S. R., Klaver, C. C., Barbazetto, I., Chang, S., Yannuzzi, L. A., Barile, G. R., Merriam, J. C., Smith, R. T., Olsh, A. K., Bergeron, J., Zernant, J., Merriam, J. E., Gold, B., Dean, M., and Allikmets, R. (2005) Proc. Natl. Acad. Sci. U. S. A. 102, 7227-7232[Abstract/Free Full Text]
  9. Edwards, A. O., Ritter, R., 3rd, Abel, K. J., Manning, A., Panhuysen, C., and Farrer, L. A. (2005) Science 308, 421-424[Abstract/Free Full Text]
  10. Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J. Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., Bracken, M. B., Ferris, F. L., Ott, J., Barnstable, C., and Hoh, J. (2005) Science 308, 385-389[Abstract/Free Full Text]
  11. Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., Schnetz-Boutaud, N., Agarwal, A., Postel, E. A., and Pericak-Vance, M. A. (2005) Science 308, 419-421[Abstract/Free Full Text]
  12. Zareparsi, S., Branham, K. E., Li, M., Shah, S., Klein, R. J., Ott, J., Hoh, J., Abecasis, G. R., and Swaroop, A. (2005) Am. J. Hum. Genet. 77, 149-153[CrossRef][Medline] [Order article via Infotrieve]
  13. Nozaki, M., Raisler, B. J., Sakurai, E., Sarma, J. V., Barnum, S. R., Lambris, J. D., Chen, Y., Zhang, K., Ambati, B. K., Baffi, J. Z., and Ambati, J. (2006) Proc. Natl. Acad. Sci. U. S. A. 103, 2328-2333[Abstract/Free Full Text]
  14. Thakkinstian, A., Han, P., McEvoy, M., Smith, W., Hoh, J., Magnusson, K., Zhang, K., and Attia, J. (2006) Hum. Mol. Genet. 15, 2784-2790[Abstract/Free Full Text]
  15. Li, M., Atmaca-Sonmez, P., Othman, M., Branham, K. E., Khanna, R., Wade, M. S., Li, Y., Liang, L., Zareparsi, S., Swaroop, A., and Abecasis, G. R. (2006) Nat. Genet. 38, 1049-1054[CrossRef][Medline] [Order article via Infotrieve]
  16. Maller, J., George, S., Purcell, S., Fagerness, J., Altshuler, D., Daly, M. J., and Seddon, J. M. (2006) Nat. Genet. 38, 1055-1059[CrossRef][Medline] [Order article via Infotrieve]
  17. Gold, B., Merriam, J. E., Zernant, J., Hancox, L. S., Taiber, A. J., Gehrs, K., Cramer, K., Neel, J., Bergeron, J., Barile, G. R., Smith, R. T., Hageman, G. S., Dean, M., Allikmets, R., Chang, S., Yannuzzi, L. A., Merriam, J. C., Barbazetto, I., Lerner, L. E., Russell, S., Hoballah, J., Hageman, J., and Stockman, H. (2006) Nat. Genet. 38, 458-462[CrossRef][Medline] [Order article via Infotrieve]
  18. Seddon, J. M., George, S., Rosner, B., and Klein, M. L. (2006) Hum. Hered. 61, 157-165[CrossRef][Medline] [Order article via Infotrieve]
  19. Sim, R. B., and DiScipio, R. G. (1982) Biochem. J. 205, 285-293[Medline] [Order article via Infotrieve]
  20. Pangburn, M. K. (2000) Immunopharmacology 49, 149-157[CrossRef][Medline] [Order article via Infotrieve]
  21. Meri, S., and Pangburn, M. K. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3982-3986[Abstract/Free Full Text]
  22. Ripoche, J., Day, A. J., Willis, A. C., Belt, K. T., Campbell, R. D., and Sim, R. B. (1986) Biosci. Rep. 6, 65-72[CrossRef][Medline] [Order article via Infotrieve]
  23. Gershov, D., Kim, S., Brot, N., and Elkon, K. B. (2000) J. Exp. Med. 192, 1353-1364[Abstract/Free Full Text]
  24. Giannakis, E., Male, D. A., Ormsby, R. J., Mold, C., Jokiranta, T. S., Ranganathan, S., and Gordon, D. L. (2001) Int. Immunopharmacol. 1, 433-443[CrossRef][Medline] [Order article via Infotrieve]
  25. Blackmore, T. K., Sadlon, T. A., Ward, H. M., Lublin, D. M., and Gordon, D. L. (1996) J. Immunol. 157, 5422-5427[Abstract]
  26. Skerka, C., Lauer, N., Weinberger, A. A. W. A., Keilhauser, C. N., Sühnel, J., Smith, R., Schlotzer-Schrehardt, U., Fritsche, L., Heinen, S., Hartmann, A., Weber, B. H. F., and Zipfel, P. F. (2007) Mol. Immunol. 44, 509-514
  27. Clark, S. J., Higman, V. A., Mulloy, B., Perkins, S. J., Lea, S. M., Sim, R. B., and Day, A. J. (2006) J. Biol. Chem. 281, 24713-24720[Abstract/Free Full Text]
  28. Pangburn, M. K., Schreiber, R. D., and Muller-Eberhard, H. J. (1977) J. Exp. Med. 146, 257-270[Abstract/Free Full Text]
  29. Herbert, A. P., Uhrin, D., Lyon, M., Pangburn, M. K., and Barlow, P. N. (2006) J. Biol. Chem. 281, 16512-16520[Abstract/Free Full Text]
  30. Vranken, W. F., Boucher, W., Stevens, T. J., Fogh, R. H., Pajon, A., Llinas, M., Ulrich, E. L., Markley, J. L., Ionides, J., and Laue, E. D. (2005) Proteins 59, 687-696[CrossRef][Medline] [Order article via Infotrieve]
  31. Cordier, F., Barfield, M., and Grzesiek, S. (2003) J. Am. Chem. Soc. 125, 15750-15751[CrossRef][Medline] [Order article via Infotrieve]
  32. Nilges, M. (1997) Fold Des. 2, S53-S57[CrossRef][Medline] [Order article via Infotrieve]
  33. Schubert, M., Labudde, D., Oschkinat, H., and Schmieder, P. (2002) J. Biomol. NMR 24, 149-154[CrossRef][Medline] [Order article via Infotrieve]
  34. Habeck, M., Rieping, W., Linge, J. P., and Nilges, M. (2004) Methods Mol. Biol. 278, 379-402[Medline] [Order article via Infotrieve]
  35. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905-921[CrossRef][Medline] [Order article via Infotrieve]
  36. Nabuurs, S. B., Spronk, C. A., Krieger, E., Maassen, H., Vriend, G., and Vuister, G. W. (2003) J. Am. Chem. Soc. 125, 12026-12034[CrossRef][Medline] [Order article via Infotrieve]
  37. Goger, B., Halden, Y., Rek, A., Mosl, R., Pye, D., Gallagher, J., and Kungl, A. J. (2002) Biochemistry 41, 1640-1646[CrossRef][Medline] [Order article via Infotrieve]
  38. Lyon, M., Deakin, J. A., Rahmoune, H., Fernig, D. G., Nakamura, T., and Gallagher, J. T. (1998) J. Biol. Chem. 273, 271-278[Abstract/Free Full Text]
  39. Lyon, M., Deakin, J. A., Lietha, D., Gherardi, E., and Gallagher, J. T. (2004) J. Biol. Chem. 279, 43560-43567[Abstract/Free Full Text]
  40. Sue, S. C., Chen, J. Y., Lee, S. C., Wu, W. G., and Huang, T. H. (2004) J. Mol. Biol. 343, 1365-1377[CrossRef][Medline] [Order article via Infotrieve]
  41. Kirkitadze, M. D., Dryden, D. T., Kelly, S. M., Price, N. C., Wang, X., Krych, M., Atkinson, J. P., and Barlow, P. N. (1999) FEBS Lett. 459, 133-138[CrossRef][Medline] [Order article via Infotrieve]
  42. Kirkitadze, M. D., and Barlow, P. N. (2001) Immunol. Rev. 180, 146-161[CrossRef][Medline] [Order article via Infotrieve]
  43. Norman, D. G., Barlow, P. N., Baron, M., Day, A. J., Sim, R. B., and Campbell, I. D. (1991) J. Mol. Biol. 219, 717-725[CrossRef][Medline] [Order article via Infotrieve]
  44. Uhrinova, S., Lin, F., Ball, G., Bromek, K., Uhrin, D., Medof, M. E., and Barlow, P. N. (2003) Proc. Natl. Acad. Sci. U. S. A. 100, 4718-4723[Abstract/Free Full Text]
  45. Soares, D. C., and Barlow, P. N. (2005) in Structural Biology of the Complement System (Morikis, D., and Lambris, J. D., eds) pp. 19-62, CRC Press, Inc., Boca Raton, FL
  46. Jokiranta, T. S., Hellwage, J., Koistinen, V., Zipfel, P. F., and Meri, S. (2000) J. Biol. Chem. 275, 27657-27662[Abstract/Free Full Text]
  47. Ormsby, R. J., Jokiranta, T. S., Duthy, T. G., Griggs, K. M., Sadlon, T. A., Giannakis, E., and Gordon, D. L. (2006) Mol. Immunol. 43, 1624-1632[CrossRef][Medline] [Order article via Infotrieve]
  48. Kuhn, S., Skerka, C., and Zipfel, P. F. (1995) J. Immunol. 155, 5663-5670[Abstract]
  49. Blackmore, T. K., Hellwage, J., Sadlon, T. A., Higgs, N., Zipfel, P. F., Ward, H. M., and Gordon, D. L. (1998) J. Immunol. 160, 3342-3348[Abstract/Free Full Text]
  50. Aslam, M., and Perkins, S. J. (2001) J. Mol. Biol. 309, 1117-1138[CrossRef][Medline] [Order article via Infotrieve]
  51. Quiocho, F. A. (1993) Biochem. Soc. Trans. 21, 442-448[Medline] [Order article via Infotrieve]
  52. Blundell, C. D., Almond, A., Mahoney, D. J., DeAngelis, P. L., Campbell, I. D., and Day, A. J. (2005) J. Biol. Chem. 280, 18189-18201[Abstract/Free Full Text]
  53. Giannakis, E., Jokiranta, T. S., Male, D. A., Ranganathan, S., Ormsby, R. J., Fischetti, V. A., Mold, C., and Gordon, D. L. (2003) Eur. J. Immunol. 33, 962-969[CrossRef][Medline] [Order article via Infotrieve]
  54. Murphy, K. J., Merry, C. L., Lyon, M., Thompson, J. E., Roberts, I. S., and Gallagher, J. T. (2004) J. Biol. Chem. 279, 27239-27245[Abstract/Free Full Text]
  55. Jokiranta, T. S., Cheng, Z. Z., Seeberger, H., Jozsi, M., Heinen, S., Noris, M., Remuzzi, G., Ormsby, R., Gordon, D. L., Meri, S., Hellwage, J., and Zipfel, P. F. (2005) Am. J. Pathol. 167, 1173-1181[Abstract/Free Full Text]
  56. Oppermann, M., Manuelian, T., Jozsi, M., Brandt, E., Jokiranta, T. S., Heinen, S., Meri, S., Skerka, C., Gotze, O., and Zipfel, P. F. (2006) Clin. Exp. Immunol. 144, 342-352[CrossRef][Medline] [Order article via Infotrieve]
  57. Licht, C., Heinen, S., Jozsi, M., Loschmann, I., Saunders, R. E., Perkins, S. J., Waldherr, R., Skerka, C., Kirschfink, M., Hoppe, B., and Zipfel, P. F. (2006) Kidney Int. 70, 42-50[CrossRef][Medline] [Order article via Infotrieve]
  58. Verdugo, M. E., and Ray, J. (1997) Exp. Eye Res. 65, 231-240[CrossRef][Medline] [Order article via Infotrieve]
  59. Ormsby, R. J., Hoh, J., Griggs, K. M., Sadlon, T. A., and Gordon, D. L. (2007) Mol. Immunol. 44, 224
  60. Laine, M., Jarva, H., Seitsonan, S., Haapasalo, K., Lehtinen, M. J., Lindeman, N., Anderson, D. H., Johnson, P. T., Jarvela, I., Jokiranta, T. S., Hagemen, G. S., Immonen, I., and Meri, S. (2007) J. Immunol. 178, 3831-3836[Abstract/Free Full Text]
  61. Jarva, H., Jokiranta, T. S., Hellwage, J., Zipfel, P. F., and Meri, S. (1999) J. Immunol. 163, 3957-3962[Abstract/Free Full Text]
  62. Nicholls, A., Sharp, K. A., and Honig, B. (1991) Proteins 11, 281-296[CrossRef][Medline] [Order article via Infotrieve]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
S. Hakobyan, C. L. Harris, C. W. van den Berg, M. C. Fernandez-Alonso, E. G. de Jorge, S. R. de Cordoba, G. Rivas, P. Mangione, M. B. Pepys, and B. P. Morgan
Complement Factor H Binds to Denatured Rather than to Native Pentameric C-reactive Protein
J. Biol. Chem., November 7, 2008; 283(45): 30451 - 30460.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Q. Schmidt, A. P. Herbert, D. Kavanagh, C. Gandy, C. J. Fenton, B. S. Blaum, M. Lyon, D. Uhrin, and P. N. Barlow
A New Map of Glycosaminoglycan and C3b Binding Sites on Factor H
J. Immunol., August 15, 2008; 181(4): 2610 - 2619.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
R. J. Ormsby, S. Ranganathan, J. C. Tong, K. M. Griggs, D. P. Dimasi, A. W. Hewitt, K. P. Burdon, J. E. Craig, J. Hoh, and D. L. Gordon
Functional and Structural Implications of the Complement Factor H Y402H Polymorphism Associated with Age-Related Macular Degeneration
Invest. Ophthalmol. Vis. Sci., May 1, 2008; 49(5): 1763 - 1770.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
B. E. Prosser, S. Johnson, P. Roversi, A. P. Herbert, B. S. Blaum, J. Tyrrell, T. A. Jowitt, S. J. Clark, E. Tarelli, D. Uhrin, et al.
Structural basis for complement factor H linked age-related macular degeneration
J. Exp. Med., October 1, 2007; 204(10): 2277 - 2283.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
R. J.H. Smith, J. Alexander, P. N. Barlow, M. Botto, T. L. Cassavant, H. T. Cook, S. R. de Cordoba, G. S. Hageman, T. S. Jokiranta, W. J. Kimberling, et al.
New Approaches to the Treatment of Dense Deposit Disease
J. Am. Soc. Nephrol., September 1, 2007; 18(9): 2447 - 2456.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
282/26/18960    most recent
M609636200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Herbert, A. P.
Right arrow Articles by Barlow, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Herbert, A. P.
Right arrow Articles by Barlow, P. N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement